Spots Global Cancer Trial Database for Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
Official Title: Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
Study ID: NCT04283539
Conditions
Interventions
Study Description
Brief Summary: This protocol is a prospective, observational study of participants receiving immunotherapy (checkpoint inhibitors, CPI) for cancer therapy, testing the hypothesis that patients with immune related cutaneous adverse events (ircAEs) have unique immunologic endotypes associated with polarized immune responses.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Jewish Health, Denver, Colorado, United States
The Melanoma and Skin Cancer Institute, Denver, Colorado, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
